Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine

Kévin Hebert; Lore Santoro; Maeva Monnier; Florence Castan; Ikrame Berkane; Eric Assénat; Cyril Fersing; Pauline Gélibert; Jean-Pierre Pouget; Manuel Bardiès; Pierre-Olivier Kotzki; Emmanuel Deshayes

doi:10.2967/jnumed.123.267023

Research ArticleClinical Investigation

Open Access

Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine

Kévin Hebert, Lore Santoro, Maeva Monnier, Florence Castan, Ikrame Berkane, Eric Assénat, Cyril Fersing, Pauline Gélibert, Jean-Pierre Pouget, Manuel Bardiès, Pierre-Olivier Kotzki and Emmanuel Deshayes

Journal of Nuclear Medicine June 2024, 65 (6) 923-930; DOI: https://doi.org/10.2967/jnumed.123.267023

Kévin Hebert

1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lore Santoro

1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;

2Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Maeva Monnier

3Biometry Unit, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Florence Castan

3Biometry Unit, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ikrame Berkane

1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Eric Assénat

4Department of Medical Oncology, CHU de Montpellier, Université de Montpellier, Montpellier, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Cyril Fersing

1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;

2Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France;

3Biometry Unit, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;

4Department of Medical Oncology, CHU de Montpellier, Université de Montpellier, Montpellier, France;

5IBMM, Université de Montpellier, CNRS, ENSCM, Montpellier, France; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Pauline Gélibert

6Centre Hospitalier Métropole Savoie, Chambéry, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jean-Pierre Pouget

2Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Manuel Bardiès

1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;

2Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Pierre-Olivier Kotzki

1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;

2Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Emmanuel Deshayes

1Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, France;

2Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Montpellier, France;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 65, Issue 6

June 1, 2024

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine

Journal of Nuclear Medicine Jun 2024, 65 (6) 923-930; DOI: 10.2967/jnumed.123.267023

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine

Journal of Nuclear Medicine Jun 2024, 65 (6) 923-930; DOI: 10.2967/jnumed.123.267023

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward!
Tumor Dose-Response Relationship of [131I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [124I]MIBG PET
Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions
Assessment of [177Lu]Lu-DOTATATE Dosimetry from High-Speed Whole-Body Recordings Provided by a 360{degrees} Cadmium-Zinc-Telluride Camera Compared with Results from a Conventional Anger-Camera Protocol
MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy
Dosimetry Software for Theranostic Applications: Current Capabilities and Future Prospects

Google Scholar

Keywords

[177Lu]Lu-DOTATATE
neuroendocrine tumors
absorbed dose–response relationship

Main menu

User menu

Search

Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords